Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
HYDROXYUREA
MYLAN PHARMACEUTICALS ULC
L01XX05
HYDROXYCARBAMIDE
500MG
CAPSULE
HYDROXYUREA 500MG
ORAL
100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0113432001; AHFS:
APPROVED
2009-07-02
_MYLAN-HYDROXYUREA (hydroxyurea capsules) _ _ _ _Page 1 of 27 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MYLAN-HYDROXYUREA Hydroxyurea Capsules Capsules, 500 mg, Oral USP Antineoplastic Agent Mylan Pharmaceuticals ULC Date of Initial Authorization: 85 Advance Road October 17, 2000 Etobicoke, Ontario M8Z 2S6 Date of Revision: Canada April 4, 2023 Submission Control Number: 268902 _MYLAN-HYDROXYUREA (hydroxyurea capsules) _ _ _ _Page 2 of 27 _ RECENT MAJOR LABEL CHANGES 1 Indications 04/2023 7 Warnings and Precautions, Carcinogenesis and Mutagenesis 04/2023 7 Warnings and Precautions, Hematologic 04/2023 7 Warnings and Precautions, Reproductive Health: Female and Male Potential 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................................... 2 TABLE OF CONTENTS ............................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................... 4 1 INDICATIONS ..................................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................................ 4 1.2 Geriatrics ............................................................................................................................................ 4 2 CONTRAINDICATIONS ....................................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ....................................................................................................... 4 4.1 Dosing Considerations ................................................ Baca dokumen lengkapnya